Crossmark

Therapeutic drug monitoring vs. pharmacogenetic testing in the context of elevated olanzapine concentrations and prior clozapine intolerability: a case study

Crossref DOI link: https://doi.org/10.1186/s12888-024-06319-5

Published Online: 2024-12-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Khorassani, Farah

Azevedo, Ricardo

Farokhpay, Reza
License Information

Text and Data Mining valid from 2024-12-04

Version of Record valid from 2024-12-04
More Information

Article History

Received: 26 April 2024

Accepted: 21 November 2024

First Online: 4 December 2024

Declarations

:

: N/A.

: The authors declare no competing interests.

: Patient provided written informed consent for their personal or clinical details to be published in this study.

Document is current

Any future updates will be listed below